Phase III Randomized Study of R-CHOP V. Dose-Adjusted EPOCH-R With Molecular Profiling in Untreated De Novo Diffuse Large B-Cell Lymphomas
收藏DataCite Commons2026-01-15 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/00006661/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
This randomized phase III trial studies rituximab when given together with two different
combination chemotherapy regimens to compare how well they work in treating patients with
diffuse large B-cell non-Hodgkin's lymphoma. Monoclonal antibodies, such as rituximab, may
block cancer growth in different ways by targeting certain cells. Drugs used in chemotherapy
work in different ways to stop the growth of cancer cells, either by killing the cells, by
stopping them from dividing, or by stopping them from spreading. Giving rituximab together
with combination chemotherapy may kill more cancer cells. It is not yet known which
combination chemotherapy regimen is more effective when given with rituximab in treating
diffuse large B-cell non-Hodgkin's lymphoma.
PURPOSE: This randomized phase III trial is studying rituximab when given together with two
different combination chemotherapy regimens to compare how well they work in treating
patients with diffuse large B-cell lymphoma.
提供机构：
Vivli
创建时间：
2021-02-09
